NCT02060253View on ClinicalTrials.gov

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
HER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

ganetespib

Given IV

DRUG

paclitaxel

Given IV

BIOLOGICAL

trastuzumab

Given IV

BIOLOGICAL

pertuzumab

Given IV

Trial Locations (2)

10016

NYU Cancer Institute, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Synta Pharmaceuticals Corp.

INDUSTRY

collaborator

New York University Cancer Institute

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02060253 - Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter